Physician profile
Paul R Millmann
NPI 1609871151
$3,502.33
in general payments reported to CMS, 2019-2025
25 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2020: $225 · 2021: $634 · 2022: $433 · 2023: $755 · 2024: $696 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518 · Education: $85.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,518.19 |
| Education | $85.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $718.60 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $580.55 | 2019-2023 | Breztri |
| Amgen INC. | $398.41 | 2019-2024 | Evenity, Repatha, Prolia |
| Abbvie INC. | $358.71 | 2021-2024 | |
| Novo Nordisk INC | $272.76 | 2020-2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.53 | 2020-2025 | Jardiance |
| Lilly USA, LLC | $237.97 | 2019-2025 | Mounjaro, Jardiance |
| Astellas Pharma US INC | $104.82 | 2019-2023 | |
| Pfizer INC. | $100.09 | 2019-2021 | |
| Abbott Laboratories | $93.58 | 2021-2025 | Proclaim, Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $65.76 | 2019-2021 | |
| Heartflow, INC. | $47.78 | 2024 | |
| Exact Sciences Corporation | $37.17 | 2023-2024 | Cologuard Collection Kit |
| Tolmar, INC. | $27.46 | 2024 | |
| Sanofi-Aventis U.S. LLC | $27.03 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $26.02 | 2022 | |
| Clarus Therapeutics INC. | $21.59 | 2021 | |
| Amarin Pharma, INC. | $19.32 | 2020 | |
| Corcept Therapeutics | $18.26 | 2025 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $15.80 | 2022 | |
| Antares Pharma, INC. | $15.71 | 2025 | Xyosted |
| Kowa Pharmaceuticals America, INC. | $15.05 | 2022 | |
| Dexcom, INC. | $14.36 | 2024 | Dexcom G6 Transmitter |
| Shire North American Group INC | $12.18 | 2019 | |
| Phathom Pharmaceuticals, INC. | $5.82 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Millmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.